Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP).

Full DD Report for TNXP

You must become a subscriber to view this report.


Recent News from (NASDAQ: TNXP)

Oryzon Genomics commences mid-stage study of Alzheimer's candidate
Spanish biotech Oryzon Genomics announces that enrollment is underway in a Phase 2b clinical trial assessing ORY-2001 in patients with mild-to-moderate Alzheimer's disease (AD). More news on: vTv Therapeutics, Biogen Inc., Tonix Pharmaceuticals Holding Corp., Healthcare stocks news, ...
Source: SeekingAlpha
Date: May, 14 2018 12:27
Tonix Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Programs Update
Interim Analysis for Phase 3 HONOR study of Tonmya® in Military-Related PTSD Expected in Third Quarter of 2018 NEW YORK, May 14, 2018 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a clinical-stage biopharmaceutical company focused on developing phar...
Source: GlobeNewswire
Date: May, 14 2018 07:00
Tonix Is A Buy For Potentially Great Return On PTSD Breakthrough
Tonix's PTSD program Tonix ( TNXP )'s lead drug candidate Tonmya, or TNX-102 SL, a proprietary low-dose cyclobenzaprine (CBP), sublingual tablet, designed for bedtime administration, is in a phase 3 trial, HONOR, as a potential treatment for PTSD (post-traumatic stress disorder). The co...
Source: SeekingAlpha
Date: May, 09 2018 11:51
Tonix: PTSD Breakthrough Or Too Risky For Stockholders?
Understanding PTSD Post Traumatic Stress Disorder is an anxiety-related disorder that involves symptoms including nightmares, flashbacks, emotional distress, heightened physical response to traumatic reminders (hyperarousal), and avoidance of traumatic reminders. PTSD follows trauma and l...
Source: SeekingAlpha
Date: May, 07 2018 15:09
Tonix Pharmaceuticals to Present at the BIO KOREA 2018 International Convention
NEW YORK, May 07, 2018 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a clinical-stage biopharmaceutical company focused on developing pharmaceutical products to treat serious neuropsychiatric conditions and biological products to improve biodefense, announce...
Source: GlobeNewswire
Date: May, 07 2018 07:00
Tonix Pharmaceuticals Receives IND Clearance by U.S. FDA for TNX-102 SL in Agitation in Alzheimer's Disease
NEW YORK, May 01, 2018 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to support the initiation of a Phase 2, potential pivotal ef...
Source: GlobeNewswire
Date: May, 01 2018 07:00
Tonix Pharmaceuticals (TNXP) Presents At MicroCap Conference 2018 - Slideshow
The following slide deck was published by Tonix Pharmaceuticals Holding Corp. in conjunction with this Read more ...
Source: SeekingAlpha
Date: April, 10 2018 12:23
Blog Exposure - Tonix Pharma Announces 50% Enrolment in Tonmya® Study for PTSD
Stock Monitor: China Pharma Holdings Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 05, 2018 / Active-Investors.com has just released a free research report on Tonix Pharma Holding Corp. (NASDAQ: TNXP ) ("Tonix"). If you want access to this report all you need to do is sign ...
Source: ACCESSWIRE IA
Date: April, 05 2018 07:10
Tonix Pharmaceuticals to present PTSD program at the MicroCap Conference in New York
Tonix Pharmaceuticals (NASDAQ: TNXP ) will present at the MicroCap Conference being held April 9-10, in New York City. More news on: Tonix Pharmaceuticals Holding Corp., Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: April, 04 2018 08:34
Tonix Pharmaceuticals to Present FDA Breakthrough Therapy-Designated PTSD Program at the MicroCap Conference in New York
First 50 Percent of Participants Enrolled in Phase 3 HONOR Study of Tonmya® (Cyclobenzaprine HCl Sublingual Tablets) for the Treatment of Military-Related PTSD Interim Results of HONOR Study Expected in Third Quarter 2018 NEW YORK, April 04, 2018 (GLOBE NEWSWIRE) -- Tonix Phar...
Source: GlobeNewswire
Date: April, 04 2018 07:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-201.201.241.421.182,534,000
2018-08-171.201.18951.24891.15257,061
2018-08-161.171.191.261.12513,492
2018-08-151.031.151.481.002,929,729
2018-08-131.101.051.101.01210,297

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-20524,589939,76455.8214Short
2018-08-1771,058108,65765.3966Short
2018-08-16124,800204,13861.1351Short
2018-08-15379,5101,027,35736.9404Short
2018-08-146,44648,32613.3386Cover

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on TNXP.


About Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP)

Logo for Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP)

Not available

 

Contact Information

 

 

Current Management

  • Seth Lederman / CEO, President
  • Leland Gershell / CFO
  • Seth Lederman / Chairman
  • Stuart Davidson /
  • Patrick Grace /
  • Donald Landry /
  • Ernest Mario /
  • Charles Mather /
  • John Rhodes /
  • Samuel Saks /

Current Share Structure

  • Market Cap: $23,020,580 - 05/11/2018
  • Authorized: 150,000,000 - 05/01/2018
  • Issue and Outstanding: 8,340,790 - 05/01/2018

 


Recent Filings from (NASDAQ: TNXP)

Prospectus filed under Rule 424(b)(3)
Filing Type: 424B3Filing Source: edgar
Filing Date: May, 17 2018
Notice from the SEC of registration effectiveness
Filing Type: EFFECTFiling Source: edgar
Filing Date: May, 16 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 14 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 11 2018
Simplified registration form
Filing Type: S-3Filing Source: edgar
Filing Date: May, 01 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 01 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 19 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 13 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 03 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 12 2018

 

 


Daily Technical Chart for (NASDAQ: TNXP)

Daily Technical Chart for (NASDAQ: TNXP)


Stay tuned for daily updates and more on (NASDAQ: TNXP)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: TNXP)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in TNXP is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of TNXP and does not buy, sell, or trade any shares of TNXP. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/